CTLA4 and endocrine system disorder: Additionally, another analysis [25] based on FAERS database also support our results suggesting anti-CTLA-4 treatment was associated with a higher reporting frequency of endocrine disorders when compared with anti-PD1/anti-PD-L1 treatment (ROR = 1.60, 95%CI 1.46–1.75).